Ordinary Adjustment in the Solactive China Biotech Index | January 2020
In the ordinary adjustment, the following composition has been implemented effective open January 13, 2020:
| Security Name | Weight |
| LIVZON PHARMACEUTICAL GROU-A | 3.5062% |
| HUALAN BIOLOGICAL ENGINEER-A | 6.0000% |
| SHANGHAI RAAS BLOOD PRODUC-A | 3.0266% |
| SINO BIOPHARMACEUTICAL LTD ORD | 6.0000% |
| 3SBIO INC | 3.4236% |
| GENSCRIPT BIOTECH CORP | 5.3912% |
| INNOVENT BIOLOGICS INC | 6.0000% |
| WUXI BIOLOGICS CAYMAN INC | 6.0000% |
| WALVAX BIOTECHNOLOGY CO-A | 6.0000% |
| BETTA PHARMACEUTICALS CO L-A | 6.0000% |
| SHENZHEN KANGTAI BIOLOGICA-A | 6.0000% |
| BGI GENOMICS CO LTD-A | 6.0000% |
| HANSOH PHARMACEUTICAL GROUP CO | 5.6628% |
| BEIJING TIANTAN BIOLOGICAL-A | 3.0833% |
| JIANGSU HENGRUI MEDICINE CO LTD CLASS A | 6.0000% |
| WUXI APPTEC CO LTD-A | 6.0000% |
| NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO LTD | 1.8099% |
| BEIGENE LTD-ADR | 6.0000% |
| CHINA BIOLOGIC PRODUCTS HOLD | 4.5350% |
| HUTCHISON CHINA MEDITECH-ADR | 3.5614% |